<DOC>
	<DOC>NCT00581854</DOC>
	<brief_summary>rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years</brief_summary>
	<brief_title>Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description>rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Untreated mantle cell lymphoma Pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>untreated mantle cell lymphoma</keyword>
</DOC>